Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2020 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $320.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax fell 34.05% year-over-year to $320.3 million, compared with a TTM value of $320.3 million through Dec 2025, down 34.05%, and an annual FY2025 reading of $320.3 million, down 34.05% over the prior year.
  • Long-Term Deferred Tax was $320.3 million for Q4 2025 at Neurocrine Biosciences, down from $368.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $536.8 million in Q2 2025 and bottomed at $310.4 million in Q3 2021.
  • Average Long-Term Deferred Tax over 4 years is $391.8 million, with a median of $378.2 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax surged 33.95% in 2024, then tumbled 34.05% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $310.4 million in 2021, then grew by 16.82% to $362.6 million in 2023, then soared by 33.95% to $485.7 million in 2024, then crashed by 34.05% to $320.3 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for NBIX at $320.3 million in Q4 2025, $368.5 million in Q3 2025, and $536.8 million in Q2 2025.